Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Broggini

Showing results (11-20 of 125) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 13, 2007
p73: a chiaroscuro gene in cancerMirko Marabese, Faina Vikhanskaya, Massimo Broggini
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
KRAS Targeting and Resistance: Anticipating the ExpectableMarika Colombo, Gloriana Ndembe, Massimo Broggini
Translational Oncology|October 19, 2016
Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDXAlice Iezzi, Elisa Caiola, Massimo Broggini
Oncotargets and Therapy|March 7, 2025
The Landscape of PARP Inhibitors in Solid CancersMarta Muzzana, Massimo Broggini, Giovanna Damia
International Journal of Cancer|November 11, 2006
In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugsMaria Antonietta Sabatino, Sara Previdi, Massimo Broggini
Cancer Management and Research|February 5, 2013
Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancerMassimo Broggini, Marina Chiara Garassino, Giovanna Damia
The Lancet. Oncology|June 9, 2015
EGFR mutations and EGFR tyrosine kinase inhibitorsValter Torri, Massimo Broggini, Marina Chiara Garassino
Molecular Cancer|June 1, 2017
Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenograftsFrancesca Ricci, Federica Guffanti, Giovanna Damia, et al.
Cancer Treatment Reviews|November 29, 2011
Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impactChiara Foroni, Massimo Broggini, Daniele Generali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2013
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letterLorenza Rimassa, Jordi Bruix, Massimo Broggini, et al.
Pageof 13

Showing results (11-20 of 125) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|April 13, 2007
p73: a chiaroscuro gene in cancerMirko Marabese, Faina Vikhanskaya, Massimo Broggini
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
KRAS Targeting and Resistance: Anticipating the ExpectableMarika Colombo, Gloriana Ndembe, Massimo Broggini
Translational Oncology|October 19, 2016
Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDXAlice Iezzi, Elisa Caiola, Massimo Broggini
Oncotargets and Therapy|March 7, 2025
The Landscape of PARP Inhibitors in Solid CancersMarta Muzzana, Massimo Broggini, Giovanna Damia
International Journal of Cancer|November 11, 2006
In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugsMaria Antonietta Sabatino, Sara Previdi, Massimo Broggini
Cancer Management and Research|February 5, 2013
Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancerMassimo Broggini, Marina Chiara Garassino, Giovanna Damia
The Lancet. Oncology|June 9, 2015
EGFR mutations and EGFR tyrosine kinase inhibitorsValter Torri, Massimo Broggini, Marina Chiara Garassino
Molecular Cancer|June 1, 2017
Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenograftsFrancesca Ricci, Federica Guffanti, Giovanna Damia, et al.
Cancer Treatment Reviews|November 29, 2011
Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impactChiara Foroni, Massimo Broggini, Daniele Generali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2013
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letterLorenza Rimassa, Jordi Bruix, Massimo Broggini, et al.
Pageof 13